The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment
Open accessAbstract
Cancer is regarded as one of the most deadly and mirthless diseases and it develops due to the uncontrolled proliferation of cells. To date, varieties of traditional medications and chemotherapies have been utilized to fight tumors. However, their immense drawbacks, such as reduced bioavailability, insufficient supply, and significant adverse effects, make their use limited. Nanotechnology has evolved rapidly in recent years and offers a wide spectrum of applications in the healthcare sectors. Nanoscale materials offer strong potential for curing cancer as they pose low risk and fewer complications. Several metal oxide NPs are being developed to diagnose or treat malignancies, but zinc oxide nanoparticles (ZnO NPs) have remarkably demonstrated their potential in the diagnosis and treatment of various types of cancers due to their biocompatibility, biodegradability, and unique physico-chemical attributes. ZnO NPs showed cancer cell specific toxicity via generation of reactive oxygen species and destruction of mitochondrial membrane potential, which leads to the activation of caspase cascades followed by apoptosis of cancerous cells. ZnO NPs have also been used as an effective carrier for targeted and sustained delivery of various plant bioactive and chemotherapeutic anticancerous drugs into tumor cells. In this review, at first we have discussed the role of ZnO NPs in diagnosis and bio-imaging of cancer cells. Secondly, we have extensively reviewed the capability of ZnO NPs as carriers of anticancerous drugs for targeted drug delivery into tumor cells, with a special focus on surface functionalization, drug-loading mechanism, and stimuli-responsive controlled release of drugs. Finally, we have critically discussed the anticancerous activity of ZnO NPs on different types of cancers along with their mode of actions. Furthermore, this review also highlights the limitations and future prospects of ZnO NPs in cancer theranostic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Neurotoxic effect of active ingredients in sunscreen products, a contemporary review
Ruszkiewicz, J. A., Pinkas, A., Ferrer, B., Peres, T. V., Tsatsakis, A., & Aschner, M. (2017) · Toxicology Reports · doi:10.1016/j.toxrep.2017.05.006 · Cited by 323
Meyers, P. A., & Gorlick, R. (1997) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70540-x · Cited by 299
Genomic instability and cancer: an introduction
Shen, Z. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq057 · Cited by 229 · cited 1×
“Genomic instability may also lead to cancer, in which increased alterations occur in the genome during the entire life cycle of dividing cells [8].”
BackgroundVilleneuve, C., Guilbeau-Frugier, C., Sicard, P., Lairez, O., Ordener, C., Duparc, T., De Paulis, D., Couderc, B., Spreux-Varoquaux, O., Tortosa, F., et al. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4373 · Cited by 134
Cited by
A review on nanoparticles: characteristics, synthesis, applications, and challenges
Altammar, K. A. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1155622 · Cited by 1,067
Plant-Based Green Synthesis of Nanoparticles: Production, Characterization and Applications
Hano, C., & Abbasi, B. H. (2021) · Biomolecules · doi:10.3390/biom12010031 · Cited by 469
Self-citationAdvancements in nanoparticle-based treatment approaches for skin cancer therapy
Zeng, L., Gowda, B. H. J., Ahmed, M. G., Abourehab, M. A. S., Chen, Z.-S., Zhang, C., Li, J., & Kesharwani, P. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01708-4 · Cited by 365
Alsaiari, N. S., Alzahrani, F. M., Amari, A., Osman, H., Harharah, H. N., Elboughdiri, N., & Tahoon, M. A. (2023) · Molecules · doi:10.3390/molecules28010463 · Cited by 357
El-Khawaga, A. M., Elsayed, M. A., Gobara, M., Suliman, A. A., Hashem, A. H., Zaher, A. A., Mohsen, M., & Salem, S. S. (2025) · Biomass Conversion and Biorefinery · doi:10.1007/s13399-023-04827-0 · Cited by 148
Metadata
- Authors
- Anjum, S., Hashim, M., Malik, S. A., Khan, M., Lorenzo, J. M., Abbasi, B. H., & Hano, C.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-09-12
- Volume
- 13
- Issue
- 18
- Pages
- 4570
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3198922546
- Cited by
- 575
- References
- 9
- FWCI
- 21.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment. https://app.cochat.ai/papers/10.3390/cancers13184570
- The paper
- Anjum, S., Hashim, M., Malik, S. A., Khan, M., Lorenzo, J. M., Abbasi, B. H., & Hano, C. (2021). Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment. Cancers. https://doi.org/10.3390/cancers13184570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.